Consistent with this, down‐regulation of BRCA1/2 expression induced by PDBAG1 leads to HR repair deficiency, providing an opportunity for the use of PARPis in non‐BRCA mutant breast cancer treatment. The gene discussed is BRCA1; the disease is breast carcinoma.